Barclays’s Takeda Pharmaceutical TAK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q2
– Sell
-150,000
Closed -$2.74M – 5070
2021
Q1
$2.74M Sell
150,000
-62,830
-30% -$1.13M ﹤0.01% 2023
2020
Q4
$3.87M Hold
212,830
– – ﹤0.01% 1700
2020
Q3
$3.8M Hold
212,830
– – ﹤0.01% 1591
2020
Q2
$3.82M Sell
212,830
-70,388
-25% -$1.26M ﹤0.01% 1572
2020
Q1
$4.3M Sell
283,218
-12,499
-4% -$227K ﹤0.01% 1596
2019
Q4
$5.84M Sell
295,717
-300
-0.1% -$5.74K ﹤0.01% 1849
2019
Q3
$5.09M Buy
296,017
+596
+0.2% +$10.3K ﹤0.01% 1837
2019
Q2
$5.23M Buy
295,421
+25,414
+9% +$462K ﹤0.01% 1827
2019
Q1
$5.5M Buy
+270,007
New +$5.43M ﹤0.01% 1592

Other funds holding TAK

Barclays's TAK Position: Q3 2026 in Review

Barclays increased its Takeda Pharmaceutical (TAK) stake by 1,255% in Q3 2026, buying an estimated $1.06M and bringing the position to 64,911 shares worth $1.18M. The position accounts for ﹤0.01% of the portfolio, ranked #2927.

Barclays first reported a position in TAK in Q4 2018 and has held it in 32 quarters since. The position peaked at $27.9M in Q1 2023. 396 funds tracked by Wall St. Rank hold TAK as of Q3 2026.

  • Barclays held 64,911 shares of Takeda Pharmaceutical worth $1.18M as of Q3 2026.
  • Barclays bought 60,119 Takeda Pharmaceutical shares in Q3 2026, an estimated $1.06M.
  • Takeda Pharmaceutical made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #2927 holding.
  • Barclays first reported a position in Takeda Pharmaceutical in Q4 2018 and has held it in 32 quarters since.
  • Barclays's Takeda Pharmaceutical position peaked at $27.9M in Q1 2023.
  • 396 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.